CLIA Kit for Isocitrate Dehydrogenase 1, Soluble (IDH1) Homo sapiens (Human) Sandwich CLIA

PICD; IDP; Oxalosuccinate decarboxylase; NADP(+)-specific ICDH; Cytosolic NADP-isocitrate dehydrogenase

  • CLIA Kit for Isocitrate Dehydrogenase 1, Soluble (IDH1) Packages (Simulation)
  • CLIA Kit for Isocitrate Dehydrogenase 1, Soluble (IDH1) Packages (Simulation)
  • CLIA Kit for Isocitrate Dehydrogenase 1, Soluble (IDH1) Results demonstration
  • SCH839Hu.jpg Typical Standard Curve
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Recovery

Matrices listed below were spiked with certain level of recombinant Isocitrate Dehydrogenase 1, Soluble (IDH1) and the recovery rates were calculated by comparing the measured value to the expected amount of Isocitrate Dehydrogenase 1, Soluble (IDH1) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 78-95 83
EDTA plasma(n=5) 87-105 98
heparin plasma(n=5) 78-104 86

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Isocitrate Dehydrogenase 1, Soluble (IDH1) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Isocitrate Dehydrogenase 1, Soluble (IDH1) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Isocitrate Dehydrogenase 1, Soluble (IDH1) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 97-104% 85-95% 93-105% 86-105%
EDTA plasma(n=5) 94-105% 86-101% 92-99% 83-103%
heparin plasma(n=5) 88-105% 95-105% 79-91% 87-102%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
Pre-coated, ready to use 96-well strip plate 1 Plate sealer for 96 wells 4
Standard 2 Standard Diluent 1×20mL
Detection Reagent A 1×120µL Assay Diluent A 1×12mL
Detection Reagent B 1×120µL Assay Diluent B 1×12mL
Substrate A 1×10mL Substrate B 1×2mL
Wash Buffer (30 × concentrate) 1×20mL Instruction manual 1

Assay procedure summary

1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 100µL Substrate Solution. Incubate 10 minutes at 37°C;
8. Read RLU value immediately.

CLIA Kit for Isocitrate Dehydrogenase 1, Soluble (IDH1)

Test principle

The microplate provided in this kit has been pre-coated with an antibody specific to Isocitrate Dehydrogenase 1, Soluble (IDH1). Standards or samples are then added to the appropriate microplate wells with a biotin-conjugated antibody specific to Isocitrate Dehydrogenase 1, Soluble (IDH1). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. Then the mixture of substrate A and B is added to generate glow light emission kinetics. Upon plate development, the intensity of the emitted light is proportional to the Isocitrate Dehydrogenase 1, Soluble (IDH1) level in the sample or standard.;

Reference

  • Molecular & Cellular ProteomicsIdentification of IDH1 as a Potential Diagnostic and Prognostic Biomarker for Non-small-cell Lung Cancer by Proteomic AnalysisMcponline: 008821
  • Molecular & Cellular ProteomicsIdentification of Isocitrate Dehydrogenase 1 as a Potential Diagnostic and Prognostic Biomarker for Non-small Cell Lung Cancer by Proteomic AnalysisPubmed: 22064513
  • Clinical Cancer ResearchIsocitrate dehydrogenase 1 is a novel plasma biomarker for the diagnosis of non-small cell lung cancerPubmed: 24046070
  • Onco Targets TherThe effects of PGC-1α on the proliferation and energy metabolism of malignant endometrial cancer cellsPubMed: 25914546

Related products for research use of Homo sapiens (Human) Organism species